Want to see JP:3750 full AI Analyst Report?
Top Page
Cytori Cell Research Institute, Inc.
(3750)
Select Model
Select Model
Rating:45Neutral
Price Target:
¥772.00
▼(-8.10% Downside)
Action:Upgraded
Date:08/18/26
The score is driven primarily by very weak financial performance, including steep revenue decline, extremely negative margins, and ongoing cash burn alongside a sharply reduced equity base. Technical indicators are mixed-to-neutral with the stock below longer-term moving averages, offering limited support. Valuation is also constrained by a negative P/E and no dividend yield provided.
Positive Factors
Gross margin recovery
The return to positive gross margin indicates that the underlying products or services generated some contribution above direct costs. If sustained, this could provide a base for recovery, although operating expenses currently overwhelm gross profit.
Negative Factors
Severe revenue contraction
The sustained collapse in revenue indicates substantial deterioration in commercial scale, product demand, or business activity. A smaller revenue base makes it harder to absorb fixed costs and rebuild profitability over the next several periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross margin recovery
The return to positive gross margin indicates that the underlying products or services generated some contribution above direct costs. If sustained, this could provide a base for recovery, although operating expenses currently overwhelm gross profit.
Read all positive factors
Cytori Cell Research Institute, Inc. (3750) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.92B
Dividend YieldN/A
Average Volume (3M)5.90K
Price to Earnings (P/E)―
Beta (1Y)0.41
Revenue Growth15.47%
EPS Growth69.34%
CountryJP
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-44.45
Shares Outstanding8,929,419
10 Day Avg. Volume2,510
30 Day Avg. Volume5,903
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)329.97
Price to Sales (P/S)142.53
P/FCF Ratio-9.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cytori Cell Research Institute, Inc. Business Overview & Revenue Model
Company Description
Operating from its Tokyo headquarters, Cytori Cell Research Institute, Inc., established in 2004 (originally FRACTALE Corporation), specializes in the comprehensive research, development, production, and distribution of medical devices related to ...
How the Company Makes Money
null...
Cytori Cell Research Institute, Inc. Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
7
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 50.99M | 122.20M | 1.56B | 2.14B | 1.34B |
| Gross Profit | 9.87M | -55.56M | 1.08B | 988.61M | 622.73M |
| EBITDA | -905.48M | -757.31M | -518.43M | -462.87M | -141.28M |
| Net Income | -396.90M | -2.14B | 138.16M | -1.06B | -77.63M |
Balance Sheet | |||||
| Total Assets | 368.06M | 3.54B | 5.82B | 14.09B | 16.01B |
| Cash, Cash Equivalents and Short-Term Investments | 125.90M | 255.98M | 1.04B | 1.12B | 851.56M |
| Total Debt | 0.00 | 2.65B | 2.47B | 8.51B | 9.27B |
| Total Liabilities | 346.03M | 2.91B | 3.02B | 11.43B | 12.29B |
| Stockholders Equity | 22.02M | 630.54M | 2.79B | 2.65B | 3.71B |
Cash Flow | |||||
| Free Cash Flow | -784.77M | -995.12M | -1.17B | -198.04M | -367.83M |
| Operating Cash Flow | -784.77M | -987.04M | -1.15B | -39.52M | -187.78M |
| Investing Cash Flow | 2.98B | 22.90M | 8.69B | -283.06M | -216.19M |
| Financing Cash Flow | -2.32B | 171.65M | -7.17B | 294.23M | 35.80M |
Cytori Cell Research Institute, Inc. Technical Analysis
Neutral
840.00
Price Trends
789.78
Negative
802.02
Negative
827.53
Negative
Market Momentum
-5.81
Positive
46.98
Neutral
38.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3750, the sentiment is Neutral. The current price of 840 is above the 20-day moving average (MA) of 783.00, above the 50-day MA of 789.78, and above the 200-day MA of 827.53, indicating a bearish trend. The MACD of -5.81 indicates Positive momentum. The RSI at 46.98 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:3750.
Cytori Cell Research Institute, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥7.07B | 96.35 | ― | 1.24% | -7.13% | ― | |
54 Neutral | ¥35.25B | -78.23 | ― | ― | 3.43% | -53.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥22.00B | -11.71 | ― | ― | ― | 6.10% | |
47 Neutral | ¥38.07B | 58.06 | ― | ― | -47.32% | ― | |
45 Neutral | ¥6.92B | -12.43 | ― | ― | 15.47% | 69.34% | |
42 Neutral | ¥9.23B | -7.98 | ― | ― | -56.16% | 3.12% |
* Healthcare Sector Average
JP:3750
Cytori Cell Research Institute, Inc.
780.00
-134.00
-14.66%
JP:4593
Healios KK
288.00
-202.00
-41.22%
JP:4599
StemRIM Inc.
351.00
46.00
15.08%
JP:4880
CellSource Co., Ltd.
343.00
-259.95
-43.11%
JP:7774
Japan Tissue Engineering Co., Ltd.
848.00
364.00
75.21%
JP:7776
CellSeed Inc.
231.00
-210.00
-47.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.